Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

DAVID M PARISER

Allopathic & Osteopathic Physicians Dermatology

NPI
1417050717
CMS profile
109604
Location
NORFOLK, VA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2021 · Entire year

$57,848.64

64 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2021 · entire year · sorted by reported total

By paying entity

PY2021 · entire year · sorted by reported total

Page 2 of 2; records 51–64 of 64 matching records. This page contains 14 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

DAVID M PARISER

NPI 1417050717 · CMS profile ID 109604

Allopathic & Osteopathic Physicians / Dermatology

NORFOLK, VA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 2 of 2; records 51–64 of 64 matching records. This page contains 14 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1417050717?year=2021&recipient=provider&page=2#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
DAVID M PARISER, NPI 1417050717, CMS profile ID 109604. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–64 of 64 matching records. This page contains 14 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1417050717?year=2021&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
APA 7
IndustryPayments. (2026). DAVID M PARISER, NPI 1417050717, CMS profile ID 109604. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–64 of 64 matching records. This page contains 14 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1417050717?year=2021&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
Bluebook
DAVID M PARISER, NPI 1417050717, CMS profile ID 109604, IndustryPayments, General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 2; records 51–64 of 64 matching records. This page contains 14 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202. https://industrypayments.org/provider/npi-1417050717?year=2021&recipient=provider&page=2#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2021

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2021 · Physicians and non-physician practitioners · CMS publication 2026-06-30

64 matching records · $57,848.64 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 64 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 51–64 of 64.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Biofrontera Inc. $3,037.5006/24/2021 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 853693389 CMS
AbbVie Inc. $17.3306/23/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 795506907 CMS
Lilly USA, LLC $16.3906/17/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 819044971 CMS
Janssen Biotech, Inc. $1.7406/15/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 788209441 CMS
Janssen Biotech, Inc. $39.0406/15/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 788209443 CMS
AbbVie Inc. $24.6906/02/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 795506901 CMS
Almirall LLC $800.0005/25/2021 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 819699589 CMS
Janssen Biotech, Inc. $11.8905/20/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 788209439 CMS
AbbVie Inc. $16.0305/13/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 795506895 CMS
LEO Pharma Inc. $12.0605/05/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 842239565 CMS
LEO Pharma Inc. $7,500.0004/29/2021 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 842239555 CMS
Regeneron Healthcare Solutions, Inc. $3,100.0003/12/2021 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 809611281 CMS
Regeneron Healthcare Solutions, Inc. $3,100.0002/12/2021 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 809611279 CMS
Janssen Biotech, Inc. $1,350.0002/02/2021 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 788209423 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $96,464.33 153
PY2020 $45,758.73 45
PY2021 $57,848.64 64
PY2022 $21,833.70 76
PY2023 $23,952.12 64
PY2024 $4,996.72 49
PY2025 $9,752.86 33

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $603,533.76 243
PY2024 Recipient $1,093.05 10
PY2024 Principal investigator $717,395.76 316
PY2023 Recipient $3,383.18 16
PY2023 Principal investigator $565,018.89 264
PY2022 Recipient $6,152.32 8
PY2022 Principal investigator $393,501.55 160
PY2021 Recipient $10,250.67 14
PY2021 Principal investigator $1,504,763.82 222
PY2020 Recipient $29,446.02 12
PY2020 Principal investigator $1,483,056.25 261
PY2019 Recipient $56,019.66 30
PY2019 Principal investigator $1,432,919.10 255

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

243 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Incyte Corporation $2,445.00 12/19/2025 Non-covered Recipient Entity
VIRGINIA CLINICAL RESEARCH INC
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240615120
Principal investigator 1 Incyte Corporation $1,487.00 12/19/2025 Non-covered Recipient Entity
VIRGINIA CLINICAL RESEARCH INC
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240615124
Principal investigator 1 Incyte Corporation $1,585.00 12/19/2025 Non-covered Recipient Entity
VIRGINIA CLINICAL RESEARCH INC
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240615128
Principal investigator 1 Incyte Corporation $1,742.00 12/19/2025 Non-covered Recipient Entity
VIRGINIA CLINICAL RESEARCH INC
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240615169
Principal investigator 1 Incyte Corporation $1,268.00 12/19/2025 Non-covered Recipient Entity
VIRGINIA CLINICAL RESEARCH INC
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240615188
Principal investigator 1 Incyte Corporation $1,268.00 12/19/2025 Non-covered Recipient Entity
VIRGINIA CLINICAL RESEARCH INC
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240615192
Principal investigator 1 Incyte Corporation $1,268.00 12/19/2025 Non-covered Recipient Entity
VIRGINIA CLINICAL RESEARCH INC
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240615196
Principal investigator 1 Incyte Corporation $1,268.00 12/19/2025 Non-covered Recipient Entity
VIRGINIA CLINICAL RESEARCH INC
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240615199
Principal investigator 1 Incyte Corporation $1,626.00 12/19/2025 Non-covered Recipient Entity
VIRGINIA CLINICAL RESEARCH INC
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240615203
Principal investigator 1 Incyte Corporation $1,626.00 12/19/2025 Non-covered Recipient Entity
VIRGINIA CLINICAL RESEARCH INC
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240615208
Principal investigator 1 Incyte Corporation $1,626.00 12/19/2025 Non-covered Recipient Entity
VIRGINIA CLINICAL RESEARCH INC
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240615214
Principal investigator 1 Incyte Corporation $2,179.00 12/19/2025 Non-covered Recipient Entity
VIRGINIA CLINICAL RESEARCH INC
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240615222
Principal investigator 1 Incyte Corporation $2,179.00 12/19/2025 Non-covered Recipient Entity
VIRGINIA CLINICAL RESEARCH INC
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240615225
Principal investigator 1 Incyte Corporation $51.00 12/19/2025 Non-covered Recipient Entity
VIRGINIA CLINICAL RESEARCH INC
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240615259
Principal investigator 1 Incyte Corporation $51.00 12/19/2025 Non-covered Recipient Entity
VIRGINIA CLINICAL RESEARCH INC
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240615265
Principal investigator 1 Incyte Corporation $51.00 12/19/2025 Non-covered Recipient Entity
VIRGINIA CLINICAL RESEARCH INC
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240615269
Principal investigator 1 Incyte Corporation $51.00 12/19/2025 Non-covered Recipient Entity
VIRGINIA CLINICAL RESEARCH INC
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240615272
Principal investigator 1 Incyte Corporation $51.00 12/19/2025 Non-covered Recipient Entity
VIRGINIA CLINICAL RESEARCH INC
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240615276
Principal investigator 1 Incyte Corporation $51.00 12/19/2025 Non-covered Recipient Entity
VIRGINIA CLINICAL RESEARCH INC
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240615280
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $275.00 12/17/2025 Covered Recipient Teaching Hospital
Cleveland Clinic Hospital
EvasayilTM : A placebo-controlled trial to evaluate the efficacy and safety of spesolimab in the treatment of patients with Netherton syndrome No dispute reported 06/30/2026 1220815222
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $2,325.55 12/17/2025 Covered Recipient Teaching Hospital
Cleveland Clinic Hospital
EvasayilTM : A placebo-controlled trial to evaluate the efficacy and safety of spesolimab in the treatment of patients with Netherton syndrome No dispute reported 06/30/2026 1220815224
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $2,600.00 12/15/2025 Non-covered Recipient Entity
Virginia Clinical Research Inc
EvasayilTM : A placebo-controlled trial to evaluate the efficacy and safety of spesolimab in the treatment of patients with Netherton syndrome No dispute reported 06/30/2026 1220795127
Principal investigator 1 Incyte Corporation $2,166.45 12/08/2025 Non-covered Recipient Entity
VIRGINIA CLINICAL RESEARCH INC
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240615173
Principal investigator 1 Incyte Corporation $6,099.80 12/05/2025 Non-covered Recipient Entity
VIRGINIA CLINICAL RESEARCH INC
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240615177
Principal investigator 1 ABBVIE INC. $4,190.80 12/04/2025 Non-covered Recipient Entity
VIRGINIA CLINICAL RESEARCH INC
A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1202528770
Principal investigator 1 ABBVIE INC. $3,073.80 12/04/2025 Non-covered Recipient Entity
VIRGINIA CLINICAL RESEARCH INC
A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy (Step-Up HS) No dispute reported 06/30/2026 1202528772
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,157.19 12/04/2025 Non-covered Recipient Entity
VIRGINIA CLINICAL RESEARCH INC
AN OPEN-LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY AND EFFICACY OF DUPILUMAB IN PATIENTS >=6 MONTHS TO <18 YEARS OF AGE WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1184268995
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $10,000.00 12/03/2025 Non-covered Recipient Entity
VIRGINIA CLINICAL RESEARCH INC
A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 60 WEEKS OF TREATMENT WITH A WITHDRAWAL AND RETREATMENT PERIOD No dispute reported 06/30/2026 1223289174
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $375.00 12/03/2025 Non-covered Recipient Entity
VIRGINIA CLINICAL RESEARCH INC
A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 60 WEEKS OF TREATMENT WITH A WITHDRAWAL AND RETREATMENT PERIOD No dispute reported 06/30/2026 1223289176
Principal investigator 1 Incyte Corporation $2.37 12/01/2025 Non-covered Recipient Entity
VIRGINIA CLINICAL RESEARCH INC
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240615165
Principal investigator 1 Incyte Corporation $1.02 12/01/2025 Non-covered Recipient Entity
VIRGINIA CLINICAL RESEARCH INC
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240615184
Principal investigator 1 Incyte Corporation $52.14 12/01/2025 Non-covered Recipient Entity
VIRGINIA CLINICAL RESEARCH INC
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240615284
Principal investigator 1 Incyte Corporation $21.33 12/01/2025 Non-covered Recipient Entity
VIRGINIA CLINICAL RESEARCH INC
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240615301
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $2,770.30 12/01/2025 Non-covered Recipient Entity
VIRGINIA CLINICAL RESEARCH INC
TAK-279-PsO-3003 A Phase 3, multi-center, open-label Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1223289039
Principal investigator 1 Incyte Corporation $128.20 11/26/2025 Non-covered Recipient Entity
VIRGINIA CLINICAL RESEARCH INC
Rollover Study for Participants Previously Enrolled in Clinical Trials of Povorcitinib No dispute reported 06/30/2026 1240615063
Principal investigator 1 Incyte Corporation $1,423.10 11/24/2025 Non-covered Recipient Entity
VIRGINIA CLINICAL RESEARCH INC
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240615181
Principal investigator 1 Incyte Corporation $2,394.00 11/24/2025 Non-covered Recipient Entity
VIRGINIA CLINICAL RESEARCH INC
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240615256
Principal investigator 1 Incyte Corporation $2,445.00 11/21/2025 Non-covered Recipient Entity
VIRGINIA CLINICAL RESEARCH INC
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240615072
Principal investigator 1 Incyte Corporation $51.00 11/21/2025 Non-covered Recipient Entity
VIRGINIA CLINICAL RESEARCH INC
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240615143
Principal investigator 1 Incyte Corporation $51.00 11/21/2025 Non-covered Recipient Entity
VIRGINIA CLINICAL RESEARCH INC
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240615147
Principal investigator 1 Incyte Corporation $51.00 11/21/2025 Non-covered Recipient Entity
VIRGINIA CLINICAL RESEARCH INC
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240615153
Principal investigator 1 Incyte Corporation $1,666.00 11/21/2025 Non-covered Recipient Entity
VIRGINIA CLINICAL RESEARCH INC
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240615249
Principal investigator 1 Incyte Corporation $1,666.00 11/21/2025 Non-covered Recipient Entity
VIRGINIA CLINICAL RESEARCH INC
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240615252
Principal investigator 1 Incyte Corporation $337.20 11/21/2025 Non-covered Recipient Entity
VIRGINIA CLINICAL RESEARCH INC
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240615287
Principal investigator 1 Incyte Corporation $1,366.00 11/21/2025 Non-covered Recipient Entity
VIRGINIA CLINICAL RESEARCH INC
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240615293
Principal investigator 1 Incyte Corporation $1,626.00 11/21/2025 Non-covered Recipient Entity
VIRGINIA CLINICAL RESEARCH INC
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240615297
Principal investigator 1 Incyte Corporation $1,500.00 11/20/2025 Non-covered Recipient Entity
VIRGINIA CLINICAL RESEARCH INC
Rollover Study for Participants Previously Enrolled in Clinical Trials of Povorcitinib No dispute reported 06/30/2026 1240615059
Principal investigator 1 Incyte Corporation $5,000.00 11/20/2025 Non-covered Recipient Entity
VIRGINIA CLINICAL RESEARCH INC
Rollover Study for Participants Previously Enrolled in Clinical Trials of Povorcitinib No dispute reported 06/30/2026 1240615067
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,021.02 11/07/2025 Non-covered Recipient Entity
VIRGINIA CLINICAL RESEARCH INC
AN OPEN-LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY AND EFFICACY OF DUPILUMAB IN PATIENTS >=6 MONTHS TO <18 YEARS OF AGE WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1184258257
Principal investigator 1 ABBVIE INC. $22,097.60 11/05/2025 Non-covered Recipient Entity
VIRGINIA CLINICAL RESEARCH INC
A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1202521853
Principal investigator 1 ABBVIE INC. $11,314.70 11/04/2025 Non-covered Recipient Entity
VIRGINIA CLINICAL RESEARCH INC
A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy (Step-Up HS) No dispute reported 06/30/2026 1202520369
Principal investigator 1 Biofrontera Inc. $530.00 10/31/2025 Non-covered Recipient Entity
VIRGINIA CLINICAL RESEARCH
STUDY TO EVALUATE THE SAFETY AND EFFICACY OFBF-200ALA(AMELUZ) AND BF-RHODOLED IN THE TREATMENT OF SUPERFICIALBASAL CELL CARCINOMA(SBCC) WITH PHOTODYNAMIC THERAPY (PDT). No dispute reported 06/30/2026 1208907720
Principal investigator 1 Incyte Corporation $1,153.80 10/28/2025 Non-covered Recipient Entity
VIRGINIA CLINICAL RESEARCH INC
Rollover Study for Participants Previously Enrolled in Clinical Trials of Povorcitinib No dispute reported 06/30/2026 1240615055
Principal investigator 1 Janssen Research & Development, LLC $6,364.80 10/23/2025 Non-covered Recipient Entity
Virginia Clinic Rsrch Inc.
A Multicenter, Open Registry of Patients With Plaque Psoriasis Who Are Candidates for Systemic Therapy Including Biologics No dispute reported 06/30/2026 1175294055
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,040.91 10/23/2025 Non-covered Recipient Entity
VIRGINIA CLINICAL RESEARCH INC
AN OPEN-LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY AND EFFICACY OF DUPILUMAB IN PATIENTS >=6 MONTHS TO <18 YEARS OF AGE WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1184252524
Principal investigator 1 Incyte Corporation $68.30 10/22/2025 Non-covered Recipient Entity
VIRGINIA CLINICAL RESEARCH INC
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240615077
Principal investigator 1 Incyte Corporation $2,445.00 10/22/2025 Non-covered Recipient Entity
VIRGINIA CLINICAL RESEARCH INC
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240615081
Principal investigator 1 Incyte Corporation $1,585.00 10/22/2025 Non-covered Recipient Entity
VIRGINIA CLINICAL RESEARCH INC
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240615085
Principal investigator 1 Incyte Corporation $1,585.00 10/22/2025 Non-covered Recipient Entity
VIRGINIA CLINICAL RESEARCH INC
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240615090
Principal investigator 1 Incyte Corporation $1,585.00 10/22/2025 Non-covered Recipient Entity
VIRGINIA CLINICAL RESEARCH INC
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240615094
Principal investigator 1 Incyte Corporation $1,585.00 10/22/2025 Non-covered Recipient Entity
VIRGINIA CLINICAL RESEARCH INC
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240615098
Principal investigator 1 Incyte Corporation $81.00 10/22/2025 Non-covered Recipient Entity
VIRGINIA CLINICAL RESEARCH INC
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240615102
Principal investigator 1 Incyte Corporation $81.00 10/22/2025 Non-covered Recipient Entity
VIRGINIA CLINICAL RESEARCH INC
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240615107
Principal investigator 1 Incyte Corporation $1,626.00 10/22/2025 Non-covered Recipient Entity
VIRGINIA CLINICAL RESEARCH INC
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240615110
Principal investigator 1 Incyte Corporation $1,626.00 10/22/2025 Non-covered Recipient Entity
VIRGINIA CLINICAL RESEARCH INC
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240615113
Principal investigator 1 Incyte Corporation $1,742.00 10/22/2025 Non-covered Recipient Entity
VIRGINIA CLINICAL RESEARCH INC
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240615132
Principal investigator 1 Incyte Corporation $1,742.00 10/22/2025 Non-covered Recipient Entity
VIRGINIA CLINICAL RESEARCH INC
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240615136
Principal investigator 1 Incyte Corporation $1,742.00 10/22/2025 Non-covered Recipient Entity
VIRGINIA CLINICAL RESEARCH INC
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240615139
Principal investigator 1 Incyte Corporation $98.00 10/22/2025 Non-covered Recipient Entity
VIRGINIA CLINICAL RESEARCH INC
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240615156
Principal investigator 1 Incyte Corporation $98.00 10/22/2025 Non-covered Recipient Entity
VIRGINIA CLINICAL RESEARCH INC
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240615161
Principal investigator 1 Incyte Corporation $51.00 10/22/2025 Non-covered Recipient Entity
VIRGINIA CLINICAL RESEARCH INC
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240615230
Principal investigator 1 Incyte Corporation $51.00 10/22/2025 Non-covered Recipient Entity
VIRGINIA CLINICAL RESEARCH INC
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240615234
Principal investigator 1 Incyte Corporation $51.00 10/22/2025 Non-covered Recipient Entity
VIRGINIA CLINICAL RESEARCH INC
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240615238
Principal investigator 1 Incyte Corporation $1,666.00 10/22/2025 Non-covered Recipient Entity
VIRGINIA CLINICAL RESEARCH INC
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240615241
Principal investigator 1 Incyte Corporation $1,666.00 10/22/2025 Non-covered Recipient Entity
VIRGINIA CLINICAL RESEARCH INC
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240615245
Principal investigator 1 Incyte Corporation $216.00 10/22/2025 Non-covered Recipient Entity
VIRGINIA CLINICAL RESEARCH INC
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240615304
Principal investigator 1 Incyte Corporation $1,331.90 10/20/2025 Non-covered Recipient Entity
VIRGINIA CLINICAL RESEARCH INC
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240615116
Principal investigator 1 Incyte Corporation $2,394.00 10/20/2025 Non-covered Recipient Entity
VIRGINIA CLINICAL RESEARCH INC
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240615218
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $398.75 10/20/2025 Non-covered Recipient Entity
VIRGINIA CLINICAL RESEARCH INC
A PROSPECTIVE OBSERVATIONAL STUDY OF PATIENTS RECEIVING DUPIXENT FOR ATOPIC DERMATITIS No dispute reported 06/30/2026 1184251544
Principal investigator 1 ABBVIE INC. $16,416.10 10/09/2025 Non-covered Recipient Entity
VIRGINIA CLINICAL RESEARCH INC
A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1202514803
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $680.85 10/03/2025 Non-covered Recipient Entity
VIRGINIA CLINICAL RESEARCH INC
AN OPEN-LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY AND EFFICACY OF DUPILUMAB IN PATIENTS >=6 MONTHS TO <18 YEARS OF AGE WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1184244589
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $4,836.60 10/01/2025 Non-covered Recipient Entity
Virginia Clinical Research Inc
EvasayilTM : A placebo-controlled trial to evaluate the efficacy and safety of spesolimab in the treatment of patients with Netherton syndrome No dispute reported 06/30/2026 1220795125
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $4,635.80 10/01/2025 Non-covered Recipient Entity
VIRGINIA CLINICAL RESEARCH INC
TAK-279-PsO-3003 A Phase 3, multi-center, open-label Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1223286065
Principal investigator 1 Incyte Corporation $51.00 09/25/2025 Non-covered Recipient Entity
VIRGINIA CLINICAL RESEARCH INC
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240614945
Principal investigator 1 Incyte Corporation $98.00 09/25/2025 Non-covered Recipient Entity
VIRGINIA CLINICAL RESEARCH INC
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240614950
Principal investigator 1 Incyte Corporation $98.00 09/25/2025 Non-covered Recipient Entity
VIRGINIA CLINICAL RESEARCH INC
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240614954
Principal investigator 1 Incyte Corporation $1,416.70 09/25/2025 Non-covered Recipient Entity
VIRGINIA CLINICAL RESEARCH INC
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240614957
Principal investigator 1 Incyte Corporation $1,666.00 09/25/2025 Non-covered Recipient Entity
VIRGINIA CLINICAL RESEARCH INC
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240614960
Principal investigator 1 Incyte Corporation $1,742.00 09/25/2025 Non-covered Recipient Entity
VIRGINIA CLINICAL RESEARCH INC
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240614964
Principal investigator 1 Incyte Corporation $1,742.00 09/25/2025 Non-covered Recipient Entity
VIRGINIA CLINICAL RESEARCH INC
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240614968
Principal investigator 1 Incyte Corporation $1,585.00 09/25/2025 Non-covered Recipient Entity
VIRGINIA CLINICAL RESEARCH INC
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240614972
Principal investigator 1 Incyte Corporation $1,585.00 09/25/2025 Non-covered Recipient Entity
VIRGINIA CLINICAL RESEARCH INC
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240614976
Principal investigator 1 Incyte Corporation $98.00 09/25/2025 Non-covered Recipient Entity
VIRGINIA CLINICAL RESEARCH INC
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240614981
Principal investigator 1 Incyte Corporation $2,445.00 09/25/2025 Non-covered Recipient Entity
VIRGINIA CLINICAL RESEARCH INC
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240614985
Principal investigator 1 Incyte Corporation $51.00 09/25/2025 Non-covered Recipient Entity
VIRGINIA CLINICAL RESEARCH INC
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240615022
Principal investigator 1 Incyte Corporation $51.00 09/25/2025 Non-covered Recipient Entity
VIRGINIA CLINICAL RESEARCH INC
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240615025
Principal investigator 1 Incyte Corporation $2,445.00 09/25/2025 Non-covered Recipient Entity
VIRGINIA CLINICAL RESEARCH INC
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240615030
Principal investigator 1 Incyte Corporation $2,445.00 09/25/2025 Non-covered Recipient Entity
VIRGINIA CLINICAL RESEARCH INC
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240615033
Principal investigator 1 Incyte Corporation $2,445.00 09/25/2025 Non-covered Recipient Entity
VIRGINIA CLINICAL RESEARCH INC
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240615037
Principal investigator 1 Incyte Corporation $2,445.00 09/25/2025 Non-covered Recipient Entity
VIRGINIA CLINICAL RESEARCH INC
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240615040
Principal investigator 1 Incyte Corporation $98.00 09/25/2025 Non-covered Recipient Entity
VIRGINIA CLINICAL RESEARCH INC
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240615045
Principal investigator 1 Incyte Corporation $1,742.00 09/25/2025 Non-covered Recipient Entity
VIRGINIA CLINICAL RESEARCH INC
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240615048
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $398.75 09/19/2025 Non-covered Recipient Entity
VIRGINIA CLINICAL RESEARCH INC
A PROSPECTIVE OBSERVATIONAL STUDY OF PATIENTS RECEIVING DUPIXENT FOR ATOPIC DERMATITIS No dispute reported 06/30/2026 1184241122
Principal investigator 1 Incyte Corporation $10,000.00 09/15/2025 Non-covered Recipient Entity
VIRGINIA CLINICAL RESEARCH INC
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240614990
Principal investigator 1 Incyte Corporation $1,500.00 09/15/2025 Non-covered Recipient Entity
VIRGINIA CLINICAL RESEARCH INC
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240614995
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $813.96 08/21/2025 Non-covered Recipient Entity
VIRGINIA CLINICAL RESEARCH INC
AN OPEN-LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY AND EFFICACY OF DUPILUMAB IN PATIENTS >=6 MONTHS TO <18 YEARS OF AGE WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1184229915
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $859.35 08/07/2025 Non-covered Recipient Entity
VIRGINIA CLINICAL RESEARCH INC
AN OPEN-LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY AND EFFICACY OF DUPILUMAB IN PATIENTS >=6 MONTHS TO <18 YEARS OF AGE WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1184226519
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $4,687.80 08/01/2025 Non-covered Recipient Entity
VIRGINIA CLINICAL RESEARCH INC
TAK-279-PsO-3003 A Phase 3, multi-center, open-label Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1223283689
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $4,403.10 08/01/2025 Non-covered Recipient Entity
VIRGINIA CLINICAL RESEARCH INC
TAK-279-PsO-3003 A Phase 3, multi-center, open-label Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1223283691
Principal investigator 1 Janssen Research & Development, LLC $7,072.00 07/31/2025 Non-covered Recipient Entity
Virginia Clinic Rsrch Inc.
A Multicenter, Open Registry of Patients With Plaque Psoriasis Who Are Candidates for Systemic Therapy Including Biologics No dispute reported 06/30/2026 1175294114
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $272.34 07/31/2025 Non-covered Recipient Entity
VIRGINIA CLINICAL RESEARCH INC
AN OPEN-LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY AND EFFICACY OF DUPILUMAB IN PATIENTS >=6 MONTHS TO <18 YEARS OF AGE WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1184222750
Principal investigator 1 Incyte Corporation $500.00 07/28/2025 Non-covered Recipient Entity
VIRGINIA CLINICAL RESEARCH INC
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240614999
Principal investigator 1 Incyte Corporation $3,000.00 07/28/2025 Non-covered Recipient Entity
VIRGINIA CLINICAL RESEARCH INC
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240615008
Principal investigator 1 Incyte Corporation $1,928.75 07/18/2025 Non-covered Recipient Entity
VIRGINIA CLINICAL RESEARCH INC
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240615005
Principal investigator 1 Incyte Corporation $1,624.00 07/18/2025 Non-covered Recipient Entity
VIRGINIA CLINICAL RESEARCH INC
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240615011
Principal investigator 1 Incyte Corporation $1,528.00 07/18/2025 Non-covered Recipient Entity
VIRGINIA CLINICAL RESEARCH INC
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240615014
Principal investigator 1 Incyte Corporation $2,231.00 07/18/2025 Non-covered Recipient Entity
VIRGINIA CLINICAL RESEARCH INC
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240615018
Principal investigator 1 Incyte Corporation $1,528.00 07/18/2025 Non-covered Recipient Entity
VIRGINIA CLINICAL RESEARCH INC
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240615052
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $398.75 07/18/2025 Non-covered Recipient Entity
VIRGINIA CLINICAL RESEARCH INC
A PROSPECTIVE OBSERVATIONAL STUDY OF PATIENTS RECEIVING DUPIXENT FOR ATOPIC DERMATITIS No dispute reported 06/30/2026 1184217495
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,157.19 07/04/2025 Non-covered Recipient Entity
VIRGINIA CLINICAL RESEARCH INC
AN OPEN-LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY AND EFFICACY OF DUPILUMAB IN PATIENTS >=6 MONTHS TO <18 YEARS OF AGE WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1184212789
Principal investigator 1 ABBVIE INC. $6,788.80 07/02/2025 Non-covered Recipient Entity
VIRGINIA CLINICAL RESEARCH INC
A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1202496261
Principal investigator 1 ABBVIE INC. $4,832.03 07/02/2025 Non-covered Recipient Entity
VIRGINIA CLINICAL RESEARCH INC
A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy (Step-Up HS) No dispute reported 06/30/2026 1202496369
Principal investigator 1 Incyte Corporation $1,451.60 06/25/2025 Non-covered Recipient Entity
VIRGINIA CLINICAL RESEARCH INC
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240614877
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $398.75 06/18/2025 Non-covered Recipient Entity
VIRGINIA CLINICAL RESEARCH INC
A PROSPECTIVE OBSERVATIONAL STUDY OF PATIENTS RECEIVING DUPIXENT FOR ATOPIC DERMATITIS No dispute reported 06/30/2026 1184208989
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $136.17 06/12/2025 Non-covered Recipient Entity
VIRGINIA CLINICAL RESEARCH INC
AN OPEN-LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY AND EFFICACY OF DUPILUMAB IN PATIENTS >=6 MONTHS TO <18 YEARS OF AGE WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1184206167
Principal investigator 1 Eli Lilly and Company $5,955.40 06/05/2025 Non-covered Recipient Entity
VIRGINIA CLINICAL RESEARCH INC
A LONG-TERM STUDY TO ASSESS THE SAFETY AND EFFICACY OF LEBRIKIZUMAB IN PATIENTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS No dispute reported 06/30/2026 1187892234
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $703.29 06/05/2025 Non-covered Recipient Entity
VIRGINIA CLINICAL RESEARCH INC
AN OPEN-LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY AND EFFICACY OF DUPILUMAB IN PATIENTS >=6 MONTHS TO <18 YEARS OF AGE WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1184204109
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,694.55 06/04/2025 Non-covered Recipient Entity
VIRGINIA CLINICAL RESEARCH INC
A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 60 WEEKS OF TREATMENT WITH A WITHDRAWAL AND RETREATMENT PERIOD No dispute reported 06/30/2026 1223280722
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $14,290.90 06/04/2025 Non-covered Recipient Entity
VIRGINIA CLINICAL RESEARCH INC
TAK-279-PsO-3003 A Phase 3, multi-center, open-label Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1223280742
Principal investigator 1 ABBVIE INC. $3,305.20 06/03/2025 Non-covered Recipient Entity
VIRGINIA CLINICAL RESEARCH INC
A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy (Step-Up HS) No dispute reported 06/30/2026 1202487613
Principal investigator 1 Incyte Corporation $39.14 06/03/2025 Non-covered Recipient Entity
VIRGINIA CLINICAL RESEARCH INC
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240614893
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,213.29 05/28/2025 Non-covered Recipient Entity
VIRGINIA CLINICAL RESEARCH INC
AN OPEN-LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY AND EFFICACY OF DUPILUMAB IN PATIENTS >=6 MONTHS TO <18 YEARS OF AGE WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1184198813
Principal investigator 1 Boehringer Ingelheim International GmbH $109.50 05/27/2025 Non-covered Recipient Entity
Virginia Clinical Research Inc
EvasayilTM : A placebo-controlled trial to evaluate the efficacy and safety of spesolimab in the treatment of patients with Netherton syndrome No dispute reported 06/30/2026 1220658252
Principal investigator 1 Boehringer Ingelheim International GmbH $13.32 05/27/2025 Non-covered Recipient Entity
Virginia Clinical Research Inc
EvasayilTM : A placebo-controlled trial to evaluate the efficacy and safety of spesolimab in the treatment of patients with Netherton syndrome No dispute reported 06/30/2026 1220658254
Principal investigator 1 Boehringer Ingelheim International GmbH $13.32 05/27/2025 Non-covered Recipient Entity
Virginia Clinical Research Inc
EvasayilTM : A placebo-controlled trial to evaluate the efficacy and safety of spesolimab in the treatment of patients with Netherton syndrome No dispute reported 06/30/2026 1220658256
Principal investigator 1 Boehringer Ingelheim International GmbH $13.32 05/27/2025 Non-covered Recipient Entity
Virginia Clinical Research Inc
EvasayilTM : A placebo-controlled trial to evaluate the efficacy and safety of spesolimab in the treatment of patients with Netherton syndrome No dispute reported 06/30/2026 1220658258
Principal investigator 1 Boehringer Ingelheim International GmbH $13.32 05/27/2025 Non-covered Recipient Entity
Virginia Clinical Research Inc
EvasayilTM : A placebo-controlled trial to evaluate the efficacy and safety of spesolimab in the treatment of patients with Netherton syndrome No dispute reported 06/30/2026 1220658260
Principal investigator 1 Incyte Corporation $2,119.45 05/21/2025 Non-covered Recipient Entity
VIRGINIA CLINICAL RESEARCH INC
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240614857
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $272.34 05/15/2025 Non-covered Recipient Entity
VIRGINIA CLINICAL RESEARCH INC
AN OPEN-LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY AND EFFICACY OF DUPILUMAB IN PATIENTS >=6 MONTHS TO <18 YEARS OF AGE WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1184194577
Principal investigator 1 PFIZER INC. $600.00 05/14/2025 Non-covered Recipient Entity
Virginia Clinical Research Inc
A PHASE 3 MULTICENTER LONGTERM EXTENSION STUDY INVESTIGATING THE EFFICACY AND SAFETY OF ABROCITINIB WITH OR WITHOUT TOPICAL MEDICATIONS ADMINISTERED TO SUBJECTS AGED 12 YEARS AND OLDER WITH MODERATE TO SEVERE ATOPIC DERMATITIS No dispute reported 06/30/2026 1228784204
Principal investigator 1 ABBVIE INC. $9,084.60 05/07/2025 Non-covered Recipient Entity
VIRGINIA CLINICAL RESEARCH INC
A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1202483321
Principal investigator 1 ABBVIE INC. $7,716.03 05/06/2025 Non-covered Recipient Entity
VIRGINIA CLINICAL RESEARCH INC
A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy (Step-Up HS) No dispute reported 06/30/2026 1202481801
Principal investigator 1 Incyte Corporation $1,340.05 05/02/2025 Non-covered Recipient Entity
VIRGINIA CLINICAL RESEARCH INC
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240614861
Principal investigator 1 Incyte Corporation $16.44 05/02/2025 Non-covered Recipient Entity
VIRGINIA CLINICAL RESEARCH INC
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240614865
Principal investigator 1 Incyte Corporation $49.36 05/02/2025 Non-covered Recipient Entity
VIRGINIA CLINICAL RESEARCH INC
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240614869
Principal investigator 1 Incyte Corporation $48.54 05/02/2025 Non-covered Recipient Entity
VIRGINIA CLINICAL RESEARCH INC
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240614871
Principal investigator 1 Incyte Corporation $160.30 05/02/2025 Non-covered Recipient Entity
VIRGINIA CLINICAL RESEARCH INC
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240614880
Principal investigator 1 Incyte Corporation $270.80 05/02/2025 Non-covered Recipient Entity
VIRGINIA CLINICAL RESEARCH INC
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240614883
Principal investigator 1 Incyte Corporation $16.44 05/02/2025 Non-covered Recipient Entity
VIRGINIA CLINICAL RESEARCH INC
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240614886
Principal investigator 1 Incyte Corporation $8.48 05/02/2025 Non-covered Recipient Entity
VIRGINIA CLINICAL RESEARCH INC
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240614905
Principal investigator 1 Incyte Corporation $2,231.00 05/02/2025 Non-covered Recipient Entity
VIRGINIA CLINICAL RESEARCH INC
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240614929
Principal investigator 1 Incyte Corporation $16.44 05/02/2025 Non-covered Recipient Entity
VIRGINIA CLINICAL RESEARCH INC
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240614932
Principal investigator 1 Incyte Corporation $16.44 05/02/2025 Non-covered Recipient Entity
VIRGINIA CLINICAL RESEARCH INC
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240614935
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $1,133.10 05/01/2025 Non-covered Recipient Entity
Virginia Clinical Research Inc
EvasayilTM : A placebo-controlled trial to evaluate the efficacy and safety of spesolimab in the treatment of patients with Netherton syndrome No dispute reported 06/30/2026 1220795123
Principal investigator 1 Janssen Research & Development, LLC $7,779.20 04/22/2025 Non-covered Recipient Entity
Virginia Clinic Rsrch Inc.
A Multicenter, Open Registry of Patients With Plaque Psoriasis Who Are Candidates for Systemic Therapy Including Biologics No dispute reported 06/30/2026 1175294176
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,131.69 04/15/2025 Non-covered Recipient Entity
VIRGINIA CLINICAL RESEARCH INC
AN OPEN-LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY AND EFFICACY OF DUPILUMAB IN PATIENTS >=6 MONTHS TO <18 YEARS OF AGE WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1184183212
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $12,978.00 04/11/2025 Non-covered Recipient Entity
Virginia Clinical Research, Inc
A Study to Evaluate Effectiveness and Safety of Deucravacitinib in Participants With Non-Pustular Palmoplantar and Genital Psoriasis No dispute reported 06/30/2026 1235991945
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $17,872.40 04/11/2025 Non-covered Recipient Entity
VIRGINIA CLINICAL RESEARCH INC
TAK-279-PsO-3003 A Phase 3, multi-center, open-label Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1223277998
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $5,905.60 04/04/2025 Non-covered Recipient Entity
Virginia Clinical Research, Inc
A Phase 3B/4, Multicenter, Randomized, Double-blind Placebo-controlled Study to Evaluate the Efficacy and Safety of Deucravacitinib in Participants With Moderate-to-severe Scalp Psoriasis (PSORIATYK SCALP) No dispute reported 06/30/2026 1235991947
Principal investigator 1 ABBVIE INC. $10,637.80 04/03/2025 Non-covered Recipient Entity
VIRGINIA CLINICAL RESEARCH INC
A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1202470576
Principal investigator 1 ABBVIE INC. $2,350.70 04/03/2025 Non-covered Recipient Entity
VIRGINIA CLINICAL RESEARCH INC
A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy (Step-Up HS) No dispute reported 06/30/2026 1202470781
Principal investigator 1 Incyte Corporation $16.14 04/02/2025 Non-covered Recipient Entity
VIRGINIA CLINICAL RESEARCH INC
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240614889
Principal investigator 1 Incyte Corporation $21.52 04/02/2025 Non-covered Recipient Entity
VIRGINIA CLINICAL RESEARCH INC
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240614897
Principal investigator 1 Incyte Corporation $21.52 04/02/2025 Non-covered Recipient Entity
VIRGINIA CLINICAL RESEARCH INC
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240614900
Principal investigator 1 Incyte Corporation $31.80 04/02/2025 Non-covered Recipient Entity
VIRGINIA CLINICAL RESEARCH INC
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240614908
Principal investigator 1 Incyte Corporation $116.60 04/02/2025 Non-covered Recipient Entity
VIRGINIA CLINICAL RESEARCH INC
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240614911
Principal investigator 1 Incyte Corporation $270.80 04/02/2025 Non-covered Recipient Entity
VIRGINIA CLINICAL RESEARCH INC
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240614915
Principal investigator 1 Incyte Corporation $42.40 04/02/2025 Non-covered Recipient Entity
VIRGINIA CLINICAL RESEARCH INC
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240614919
Principal investigator 1 Incyte Corporation $42.40 04/02/2025 Non-covered Recipient Entity
VIRGINIA CLINICAL RESEARCH INC
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240614923
Principal investigator 1 Incyte Corporation $10.76 04/02/2025 Non-covered Recipient Entity
VIRGINIA CLINICAL RESEARCH INC
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240614927
Principal investigator 1 Incyte Corporation $21.20 04/02/2025 Non-covered Recipient Entity
VIRGINIA CLINICAL RESEARCH INC
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240614938
Principal investigator 1 Incyte Corporation $21.20 04/02/2025 Non-covered Recipient Entity
VIRGINIA CLINICAL RESEARCH INC
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240614942
Principal investigator 1 Boehringer Ingelheim International GmbH $109.50 03/25/2025 Non-covered Recipient Entity
Virginia Clinical Research Inc
EvasayilTM : A placebo-controlled trial to evaluate the efficacy and safety of spesolimab in the treatment of patients with Netherton syndrome No dispute reported 06/30/2026 1220658238
Principal investigator 1 Boehringer Ingelheim International GmbH $20.73 03/25/2025 Non-covered Recipient Entity
Virginia Clinical Research Inc
EvasayilTM : A placebo-controlled trial to evaluate the efficacy and safety of spesolimab in the treatment of patients with Netherton syndrome No dispute reported 06/30/2026 1220658240
Principal investigator 1 Boehringer Ingelheim International GmbH $4.44 03/25/2025 Non-covered Recipient Entity
Virginia Clinical Research Inc
EvasayilTM : A placebo-controlled trial to evaluate the efficacy and safety of spesolimab in the treatment of patients with Netherton syndrome No dispute reported 06/30/2026 1220658242
Principal investigator 1 Boehringer Ingelheim International GmbH $4.44 03/25/2025 Non-covered Recipient Entity
Virginia Clinical Research Inc
EvasayilTM : A placebo-controlled trial to evaluate the efficacy and safety of spesolimab in the treatment of patients with Netherton syndrome No dispute reported 06/30/2026 1220658244
Principal investigator 1 Boehringer Ingelheim International GmbH $4.44 03/25/2025 Non-covered Recipient Entity
Virginia Clinical Research Inc
EvasayilTM : A placebo-controlled trial to evaluate the efficacy and safety of spesolimab in the treatment of patients with Netherton syndrome No dispute reported 06/30/2026 1220658246
Principal investigator 1 Boehringer Ingelheim International GmbH $4.44 03/25/2025 Non-covered Recipient Entity
Virginia Clinical Research Inc
EvasayilTM : A placebo-controlled trial to evaluate the efficacy and safety of spesolimab in the treatment of patients with Netherton syndrome No dispute reported 06/30/2026 1220658248
Principal investigator 1 Boehringer Ingelheim International GmbH $0.94 03/25/2025 Non-covered Recipient Entity
Virginia Clinical Research Inc
EvasayilTM : A placebo-controlled trial to evaluate the efficacy and safety of spesolimab in the treatment of patients with Netherton syndrome No dispute reported 06/30/2026 1220658250
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $398.75 03/19/2025 Non-covered Recipient Entity
VIRGINIA CLINICAL RESEARCH INC
A PROSPECTIVE OBSERVATIONAL STUDY OF PATIENTS RECEIVING DUPIXENT FOR ATOPIC DERMATITIS No dispute reported 06/30/2026 1184174282
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $398.75 03/19/2025 Non-covered Recipient Entity
VIRGINIA CLINICAL RESEARCH INC
A PROSPECTIVE OBSERVATIONAL STUDY OF PATIENTS RECEIVING DUPIXENT FOR ATOPIC DERMATITIS No dispute reported 06/30/2026 1184174284
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $317.73 03/19/2025 Non-covered Recipient Entity
VIRGINIA CLINICAL RESEARCH INC
AN OPEN-LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY AND EFFICACY OF DUPILUMAB IN PATIENTS >=6 MONTHS TO <18 YEARS OF AGE WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1184174466
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $3,873.60 03/13/2025 Non-covered Recipient Entity
Virginia Clinical Research Inc
EvasayilTM : A placebo-controlled trial to evaluate the efficacy and safety of spesolimab in the treatment of patients with Netherton syndrome No dispute reported 06/30/2026 1220795121
Principal investigator 1 Eli Lilly and Company $93,358.00 03/11/2025 Non-covered Recipient Entity
VIRGINIA CLINICAL RESEARCH INC
EFFICACY AND SAFETY OF IXEKIZUMAB OR IXEKIZUMAB CONCOMITANTLY ADMINISTERED WITH TIRZEPATIDE IN ADULT PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS AND OBESITY OR OVERWEIGHT: A PHASE 3B, RANDOMIZED, MULTICENTER, OPEN-LABEL STUDY (TOGETHER-PSO) No dispute reported 06/30/2026 1187892918
Principal investigator 1 ABBVIE INC. $2,518.40 03/07/2025 Non-covered Recipient Entity
VIRGINIA CLINICAL RESEARCH INC
M20-465 - A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1202459791
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $2,441.40 03/07/2025 Non-covered Recipient Entity
VIRGINIA CLINICAL RESEARCH INC
A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 60 WEEKS OF TREATMENT WITH A WITHDRAWAL AND RETREATMENT PERIOD No dispute reported 06/30/2026 1223276119
Principal investigator 1 ABBVIE INC. $8,586.70 03/06/2025 Non-covered Recipient Entity
VIRGINIA CLINICAL RESEARCH INC
M23-698 - A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy (Step-Up HS) No dispute reported 06/30/2026 1202456876
Principal investigator 1 ABBVIE INC. $5,805.00 03/04/2025 Non-covered Recipient Entity
VIRGINIA CLINICAL RESEARCH INC
M23-696 - A Study to Evaluate Adverse Events and Change in Disease Activity Comparing Oral Upadacitinib to Subcutaneous Dupilumab in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis (Level Up) No dispute reported 06/30/2026 1202455643
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $768.57 03/04/2025 Non-covered Recipient Entity
VIRGINIA CLINICAL RESEARCH INC
AN OPEN-LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY AND EFFICACY OF DUPILUMAB IN PATIENTS >=6 MONTHS TO <18 YEARS OF AGE WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1184156668
Principal investigator 1 Incyte Corporation $1,293.65 03/03/2025 Non-covered Recipient Entity
VIRGINIA CLINICAL RESEARCH INC
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240614770
Principal investigator 1 Incyte Corporation $1,631.00 03/03/2025 Non-covered Recipient Entity
VIRGINIA CLINICAL RESEARCH INC
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240614790
Principal investigator 1 Incyte Corporation $54.76 03/03/2025 Non-covered Recipient Entity
VIRGINIA CLINICAL RESEARCH INC
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240614817
Principal investigator 1 Incyte Corporation $135.40 03/03/2025 Non-covered Recipient Entity
VIRGINIA CLINICAL RESEARCH INC
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240614820
Principal investigator 1 Incyte Corporation $109.52 03/03/2025 Non-covered Recipient Entity
VIRGINIA CLINICAL RESEARCH INC
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240614831
Principal investigator 1 Incyte Corporation $1,528.00 03/03/2025 Non-covered Recipient Entity
VIRGINIA CLINICAL RESEARCH INC
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240614835
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $15,975.70 02/26/2025 Non-covered Recipient Entity
VIRGINIA CLINICAL RESEARCH INC
TAK-279-PsO-3003 A Phase 3, multi-center, open-label Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1223275589
Principal investigator 1 Boehringer Ingelheim International GmbH $39.96 02/25/2025 Non-covered Recipient Entity
Virginia Clinical Research Inc
EvasayilTM : A placebo-controlled trial to evaluate the efficacy and safety of spesolimab in the treatment of patients with Netherton syndrome No dispute reported 06/30/2026 1220658234
Principal investigator 1 Boehringer Ingelheim International GmbH $36.50 02/25/2025 Non-covered Recipient Entity
Virginia Clinical Research Inc
EvasayilTM : A placebo-controlled trial to evaluate the efficacy and safety of spesolimab in the treatment of patients with Netherton syndrome No dispute reported 06/30/2026 1220658236
Principal investigator 1 Eli Lilly and Company $2,577.47 02/25/2025 Non-covered Recipient Entity
VIRGINIA CLINICAL RESEARCH INC
EFFICACY AND SAFETY OF IXEKIZUMAB OR IXEKIZUMAB CONCOMITANTLY ADMINISTERED WITH TIRZEPATIDE IN ADULT PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS AND OBESITY OR OVERWEIGHT: A PHASE 3B, RANDOMIZED, MULTICENTER, OPEN-LABEL STUDY (TOGETHER-PSO) No dispute reported 06/30/2026 1187892236
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $272.34 02/25/2025 Non-covered Recipient Entity
VIRGINIA CLINICAL RESEARCH INC
AN OPEN-LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY AND EFFICACY OF DUPILUMAB IN PATIENTS >=6 MONTHS TO <18 YEARS OF AGE WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1184155636
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $904.74 02/11/2025 Non-covered Recipient Entity
VIRGINIA CLINICAL RESEARCH INC
AN OPEN-LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY AND EFFICACY OF DUPILUMAB IN PATIENTS >=6 MONTHS TO <18 YEARS OF AGE WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1184153162
Principal investigator 1 ABBVIE INC. $2,671.40 02/06/2025 Non-covered Recipient Entity
VIRGINIA CLINICAL RESEARCH INC
M20-465 - A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1202447024
Principal investigator 1 ABBVIE INC. $4,198.30 02/05/2025 Non-covered Recipient Entity
VIRGINIA CLINICAL RESEARCH INC
M23-698 - A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy (Step-Up HS) No dispute reported 06/30/2026 1202444047
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $175.00 02/01/2025 Non-covered Recipient Entity
Virginia Clinical Research Inc
EvasayilTM : A placebo-controlled trial to evaluate the efficacy and safety of spesolimab in the treatment of patients with Netherton syndrome No dispute reported 06/30/2026 1220795117
Principal investigator 1 Novartis Pharmaceuticals Corporation $22,810.81 02/01/2025 Non-covered Recipient Entity
VIRGINIA CLINICAL RESEARCH, INC
24 Weeks Double-blind Randomized Placebo-controlled Trial to Evaluate Efficacy, PK, Safety of LOU064 in Adolescents (12 - <18) With CSU and Inadequate Response to H1-antihistamine Followed by Optional 3 Years Open-label Extension and an Optional 3 Years S No dispute reported 06/30/2026 1190306065
Principal investigator 1 Boehringer Ingelheim International GmbH $39.96 01/27/2025 Non-covered Recipient Entity
Virginia Clinical Research Inc
EvasayilTM : A placebo-controlled trial to evaluate the efficacy and safety of spesolimab in the treatment of patients with Netherton syndrome No dispute reported 06/30/2026 1220658218
Principal investigator 1 Boehringer Ingelheim International GmbH $109.50 01/27/2025 Non-covered Recipient Entity
Virginia Clinical Research Inc
EvasayilTM : A placebo-controlled trial to evaluate the efficacy and safety of spesolimab in the treatment of patients with Netherton syndrome No dispute reported 06/30/2026 1220658220
Principal investigator 1 Boehringer Ingelheim International GmbH $20.73 01/27/2025 Non-covered Recipient Entity
Virginia Clinical Research Inc
EvasayilTM : A placebo-controlled trial to evaluate the efficacy and safety of spesolimab in the treatment of patients with Netherton syndrome No dispute reported 06/30/2026 1220658222
Principal investigator 1 Boehringer Ingelheim International GmbH $8.88 01/27/2025 Non-covered Recipient Entity
Virginia Clinical Research Inc
EvasayilTM : A placebo-controlled trial to evaluate the efficacy and safety of spesolimab in the treatment of patients with Netherton syndrome No dispute reported 06/30/2026 1220658224
Principal investigator 1 Boehringer Ingelheim International GmbH $8.88 01/27/2025 Non-covered Recipient Entity
Virginia Clinical Research Inc
EvasayilTM : A placebo-controlled trial to evaluate the efficacy and safety of spesolimab in the treatment of patients with Netherton syndrome No dispute reported 06/30/2026 1220658226
Principal investigator 1 Boehringer Ingelheim International GmbH $8.88 01/27/2025 Non-covered Recipient Entity
Virginia Clinical Research Inc
EvasayilTM : A placebo-controlled trial to evaluate the efficacy and safety of spesolimab in the treatment of patients with Netherton syndrome No dispute reported 06/30/2026 1220658228
Principal investigator 1 Boehringer Ingelheim International GmbH $8.88 01/27/2025 Non-covered Recipient Entity
Virginia Clinical Research Inc
EvasayilTM : A placebo-controlled trial to evaluate the efficacy and safety of spesolimab in the treatment of patients with Netherton syndrome No dispute reported 06/30/2026 1220658230
Principal investigator 1 Boehringer Ingelheim International GmbH $0.94 01/27/2025 Non-covered Recipient Entity
Virginia Clinical Research Inc
EvasayilTM : A placebo-controlled trial to evaluate the efficacy and safety of spesolimab in the treatment of patients with Netherton syndrome No dispute reported 06/30/2026 1220658232
Principal investigator 1 Incyte Corporation $1,451.60 01/27/2025 Non-covered Recipient Entity
VIRGINIA CLINICAL RESEARCH INC
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240614827
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $3,092.70 01/24/2025 Non-covered Recipient Entity
VIRGINIA CLINICAL RESEARCH INC
A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 60 WEEKS OF TREATMENT WITH A WITHDRAWAL AND RETREATMENT PERIOD No dispute reported 06/30/2026 1223274455
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $8,181.90 01/23/2025 Non-covered Recipient Entity
Virginia Clinical Research Inc
EvasayilTM : A placebo-controlled trial to evaluate the efficacy and safety of spesolimab in the treatment of patients with Netherton syndrome No dispute reported 06/30/2026 1220795119
Principal investigator 1 Janssen Research & Development, LLC $5,448.67 01/22/2025 Non-covered Recipient Entity
Virginia Clinic Rsrch Inc.
A Multicenter, Open Registry of Patients With Plaque Psoriasis Who Are Candidates for Systemic Therapy Including Biologics No dispute reported 06/30/2026 1175294158
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,349.46 01/21/2025 Non-covered Recipient Entity
VIRGINIA CLINICAL RESEARCH INC
AN OPEN-LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY AND EFFICACY OF DUPILUMAB IN PATIENTS >=6 MONTHS TO <18 YEARS OF AGE WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1184149020
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $181.56 01/17/2025 Non-covered Recipient Entity
VIRGINIA CLINICAL RESEARCH INC
AN OPEN-LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY AND EFFICACY OF DUPILUMAB IN PATIENTS >=6 MONTHS TO <18 YEARS OF AGE WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1184148051
Principal investigator 1 Incyte Corporation $1,631.00 01/15/2025 Non-covered Recipient Entity
VIRGINIA CLINICAL RESEARCH INC
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240614766
Principal investigator 1 Incyte Corporation $1,528.00 01/15/2025 Non-covered Recipient Entity
VIRGINIA CLINICAL RESEARCH INC
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240614774
Principal investigator 1 Incyte Corporation $1,528.00 01/15/2025 Non-covered Recipient Entity
VIRGINIA CLINICAL RESEARCH INC
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240614779
Principal investigator 1 Incyte Corporation $1,133.00 01/15/2025 Non-covered Recipient Entity
VIRGINIA CLINICAL RESEARCH INC
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240614784
Principal investigator 1 Incyte Corporation $1,631.00 01/15/2025 Non-covered Recipient Entity
VIRGINIA CLINICAL RESEARCH INC
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240614787
Principal investigator 1 Incyte Corporation $380.00 01/15/2025 Non-covered Recipient Entity
VIRGINIA CLINICAL RESEARCH INC
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240614823
Principal investigator 1 Incyte Corporation $1,631.00 01/15/2025 Non-covered Recipient Entity
VIRGINIA CLINICAL RESEARCH INC
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240614853
Principal investigator 1 Novartis Pharmaceuticals Corporation $39.76 01/15/2025 Non-covered Recipient Entity
VIRGINIA CLINICAL RESEARCH, INC
A Multicenter, Double-blind, Randomized Withdrawal Extension Study of Subcutaneous Secukinumab to Demonstrate Long-term Efficacy, Safety and Tolerability in Subjects With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1190306063
Principal investigator 1 PFIZER INC. $1,097.10 01/15/2025 Non-covered Recipient Entity
Virginia Clinical Research Inc
A PHASE 3 MULTICENTER LONGTERM EXTENSION STUDY INVESTIGATING THE EFFICACY AND SAFETY OF ABROCITINIB WITH OR WITHOUT TOPICAL MEDICATIONS ADMINISTERED TO SUBJECTS AGED 12 YEARS AND OLDER WITH MODERATE TO SEVERE ATOPIC DERMATITIS No dispute reported 06/30/2026 1228800069
Principal investigator 1 Eli Lilly and Company $94.30 01/09/2025 Non-covered Recipient Entity
NEW HORIZON RESEARCH CENTER
A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 3 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF BARICITINIB IN ADULT PATIENTS WITH SEVERE ALOPECIA AREATA No dispute reported 06/30/2026 1187885916
Principal investigator 1 Eli Lilly and Company $30,060.20 01/07/2025 Non-covered Recipient Entity
VIRGINIA CLINICAL RESEARCH INC
A PHASE 3, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED TRIAL TO EVALUATE THE EFFICACY, SAFETY, AND PHARMACOKINETICS (PK) OF BARICITINIB IN CHILDREN FROM 6 YEARS TO LESS THAN 18 YEARS OF AGE WITH ALOPECIA AREATA No dispute reported 06/30/2026 1187892238
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $363.12 01/07/2025 Non-covered Recipient Entity
VIRGINIA CLINICAL RESEARCH INC
AN OPEN-LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY AND EFFICACY OF DUPILUMAB IN PATIENTS >=6 MONTHS TO <18 YEARS OF AGE WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1184145712
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $2,226.90 01/03/2025 Non-covered Recipient Entity
VIRGINIA CLINICAL RESEARCH INC
A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 60 WEEKS OF TREATMENT WITH A WITHDRAWAL AND RETREATMENT PERIOD No dispute reported 06/30/2026 1223273509
Principal investigator 1 Incyte Corporation $68.70 01/02/2025 Non-covered Recipient Entity
VIRGINIA CLINICAL RESEARCH INC
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240614794
Principal investigator 1 Incyte Corporation $62.27 01/02/2025 Non-covered Recipient Entity
VIRGINIA CLINICAL RESEARCH INC
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240614799
Principal investigator 1 Incyte Corporation $2.12 01/02/2025 Non-covered Recipient Entity
VIRGINIA CLINICAL RESEARCH INC
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240614803
Principal investigator 1 Incyte Corporation $10.30 01/02/2025 Non-covered Recipient Entity
VIRGINIA CLINICAL RESEARCH INC
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240614807
Principal investigator 1 Incyte Corporation $8.22 01/02/2025 Non-covered Recipient Entity
VIRGINIA CLINICAL RESEARCH INC
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240614811
Principal investigator 1 Incyte Corporation $24.68 01/02/2025 Non-covered Recipient Entity
VIRGINIA CLINICAL RESEARCH INC
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240614815
Principal investigator 1 Incyte Corporation $8.22 01/02/2025 Non-covered Recipient Entity
VIRGINIA CLINICAL RESEARCH INC
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240614839
Principal investigator 1 Incyte Corporation $8.22 01/02/2025 Non-covered Recipient Entity
VIRGINIA CLINICAL RESEARCH INC
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240614843
Principal investigator 1 Incyte Corporation $8.22 01/02/2025 Non-covered Recipient Entity
VIRGINIA CLINICAL RESEARCH INC
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240614847
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $175.00 01/01/2025 Non-covered Recipient Entity
Virginia Clinical Research Inc
EvasayilTM : A placebo-controlled trial to evaluate the efficacy and safety of spesolimab in the treatment of patients with Netherton syndrome No dispute reported 06/30/2026 1220795115
Principal investigator 1 PFIZER INC. $1,081.00 01/01/2025 Non-covered Recipient Entity
Virginia Clinical Research Inc
A PHASE 3 MULTICENTER LONGTERM EXTENSION STUDY INVESTIGATING THE EFFICACY AND SAFETY OF ABROCITINIB WITH OR WITHOUT TOPICAL MEDICATIONS ADMINISTERED TO SUBJECTS AGED 12 YEARS AND OLDER WITH MODERATE TO SEVERE ATOPIC DERMATITIS No dispute reported 06/30/2026 1228799971